Research Progress on RET Fusion in Non-Small-Cell Lung Cancer

Lu Zhao; Qingyun Mei; Yongchao Yu; Na Wang; Dou Zhang; Dongying Liao; Jinhui Zuo; Hongxia Xie; Yingjie Jia; Fanming Kong

doi:10.3389/fonc.2022.894214

Research Progress on RET Fusion in Non-Small-Cell Lung Cancer

Front Oncol. 2022 May 30:12:894214. doi: 10.3389/fonc.2022.894214. eCollection 2022.

Authors

Lu Zhao^{1

2}, Qingyun Mei^{1

2}, Yongchao Yu^{1

2}, Na Wang^{1

2}, Dou Zhang^{1

2}, Dongying Liao^{1

2}, Jinhui Zuo^{1

2}, Hongxia Xie^{1

2}, Yingjie Jia^{1

2}, Fanming Kong^{1

2}

Affiliations

¹ Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
² National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.

Abstract

Great progress has been made in the treatment of driver gene-positive Non- Small Cell Lung Cancer (NSCLC) in recent years. RET fusion was seen in 0.7% to 2% of NSCLC and was associated with younger age and never-smoker status. The pralsetinib and selpercatinib for RET fusion NSCLC was recommended by the 2021 NSCLC treatment guidelines. This review outlines the research progress in the treatment of RET fusion NSCLC, identifies current challenges and describes proposals for improving the outlook for these patients.

Keywords: NSCLC; RET fusion; drug resistance; immunotherapy; targeted therapy.

Publication types

Review